Market revenue in 2023 | USD 8,968.0 million |
Market revenue in 2030 | USD 15,165.2 million |
Growth rate | 7.8% (CAGR from 2023 to 2030) |
Largest segment | Conventional drugs (small molecules) |
Fastest growing segment | Biologics & Biosimilars (Large Molecules) |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biologics & Biosimilars (Large Molecules), Conventional Drugs (Small Molecules) |
Key market players worldwide | Roche Holding AG ADR, Novartis AG ADR, GlaxoSmithKline, Pfizer Inc, Merck & Co Inc, AstraZeneca PLC, Johnson & Johnson, Sanofi SA, Eli Lilly and Co, AbbVie Inc, Thermo Fisher Scientific Inc, Wuxi AppTec Co Ltd, Samsung BioLogics, FUJIFILM Holdings Corp, Lonza Group Ltd, Catalent Inc, Jubilant Pharmova |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical manufacturing market will help companies and investors design strategic landscapes.
Conventional drugs (small molecules) was the largest segment with a revenue share of 63.05% in 2023. Horizon Databook has segmented the Middle East & Africa pharmaceutical manufacturing market based on biologics & biosimilars (large molecules), conventional drugs (small molecules) covering the revenue growth of each sub-segment from 2018 to 2030.
The Middle East & Africa region has witnessed gradual developments in its pharmaceutical manufacturing industry, with more than 140 locally operational entities. The presence of global manufacturers in the region has boosted the market.
The top 10 companies, including Sanofi, Novartis, Pfizer, GSK, Novo Nordisk, MSD, and AstraZeneca, have captured 37% of the MEA market. Novo Nordisk's growth is major driven by Norditropin (somatropin), Victoza (liraglutide), and Saxenda (liraglutide).
In addition, increasing focus by regional government authorities on the wellbeing of their growing populations, coupled with advancements in healthcare services, is expected to propel the market over the forecast period.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa pharmaceutical manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa pharmaceutical manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account